EP3820482A4 - Tumorreduktionsmittelformulierungen und verfahren zur verwendung davon - Google Patents
Tumorreduktionsmittelformulierungen und verfahren zur verwendung davon Download PDFInfo
- Publication number
- EP3820482A4 EP3820482A4 EP19841949.1A EP19841949A EP3820482A4 EP 3820482 A4 EP3820482 A4 EP 3820482A4 EP 19841949 A EP19841949 A EP 19841949A EP 3820482 A4 EP3820482 A4 EP 3820482A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- methods
- tumor reduction
- formulations
- reduction formulations
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862695613P | 2018-07-09 | 2018-07-09 | |
| PCT/US2019/040264 WO2020023191A1 (en) | 2018-07-09 | 2019-07-02 | Tumor reduction formulations and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP3820482A1 EP3820482A1 (de) | 2021-05-19 |
| EP3820482A4 true EP3820482A4 (de) | 2022-03-23 |
Family
ID=75267393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP19841949.1A Withdrawn EP3820482A4 (de) | 2018-07-09 | 2019-07-02 | Tumorreduktionsmittelformulierungen und verfahren zur verwendung davon |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP3820482A4 (de) |
| JP (1) | JP2021530482A (de) |
| KR (1) | KR20220098082A (de) |
| CN (1) | CN112584841A (de) |
| AU (1) | AU2019309757A1 (de) |
| BR (1) | BR112021000279A8 (de) |
| CA (1) | CA3105717A1 (de) |
| EA (1) | EA202190201A1 (de) |
| IL (1) | IL280000A (de) |
| PH (1) | PH12021550033A1 (de) |
| WO (1) | WO2020023191A1 (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3140042A1 (en) | 2019-05-14 | 2020-11-19 | Tyme, Inc. | Compositions and methods for treating cancer |
| IL293706A (en) * | 2019-12-09 | 2022-08-01 | Tyme Inc | Pharmacy preparations and methods |
| US10905698B1 (en) | 2020-05-14 | 2021-02-02 | Tyme, Inc. | Methods of treating SARS-COV-2 infections |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080306137A1 (en) * | 2006-02-20 | 2008-12-11 | Beijing Century Biocom Pharmaceutical Technology Co., Ltd. | Pharmaceutical compositions comprising docetaxel and methods for preparation thereof |
| WO2017160895A1 (en) * | 2016-03-15 | 2017-09-21 | Tyme, Inc. | Pharmaceutical compositions for the treatment of cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20060135729A (ko) * | 2004-01-29 | 2006-12-29 | 백스터 인터내셔널 인코포레이티드 | 중추신경계 전달 증가를 위한 항레트로바이러스제의나노현탁액 |
| WO2006099685A1 (en) * | 2005-03-24 | 2006-09-28 | Medical Therapies Limited | Method for the prophylaxis or treatment of carcinomas |
| AU2015287749B2 (en) * | 2014-07-11 | 2021-03-11 | The Regents Of The University Of California | Tumor selective macropinocytosis-dependent rapidly internalizing antibodies |
| US9687528B2 (en) * | 2014-12-23 | 2017-06-27 | Steven Hoffman | Transdermal formulations |
-
2019
- 2019-07-02 CN CN201980054337.1A patent/CN112584841A/zh active Pending
- 2019-07-02 EA EA202190201A patent/EA202190201A1/ru unknown
- 2019-07-02 JP JP2021500520A patent/JP2021530482A/ja not_active Withdrawn
- 2019-07-02 BR BR112021000279A patent/BR112021000279A8/pt not_active Application Discontinuation
- 2019-07-02 EP EP19841949.1A patent/EP3820482A4/de not_active Withdrawn
- 2019-07-02 KR KR1020217003523A patent/KR20220098082A/ko active Search and Examination
- 2019-07-02 AU AU2019309757A patent/AU2019309757A1/en not_active Abandoned
- 2019-07-02 CA CA3105717A patent/CA3105717A1/en active Pending
- 2019-07-02 WO PCT/US2019/040264 patent/WO2020023191A1/en unknown
-
2021
- 2021-01-06 PH PH12021550033A patent/PH12021550033A1/en unknown
- 2021-01-07 IL IL280000A patent/IL280000A/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080306137A1 (en) * | 2006-02-20 | 2008-12-11 | Beijing Century Biocom Pharmaceutical Technology Co., Ltd. | Pharmaceutical compositions comprising docetaxel and methods for preparation thereof |
| WO2017160895A1 (en) * | 2016-03-15 | 2017-09-21 | Tyme, Inc. | Pharmaceutical compositions for the treatment of cancer |
Non-Patent Citations (1)
| Title |
|---|
| See also references of WO2020023191A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112584841A (zh) | 2021-03-30 |
| EA202190201A1 (ru) | 2021-04-09 |
| BR112021000279A2 (pt) | 2021-04-06 |
| AU2019309757A1 (en) | 2021-03-04 |
| PH12021550033A1 (en) | 2021-09-20 |
| JP2021530482A (ja) | 2021-11-11 |
| KR20220098082A (ko) | 2022-07-11 |
| EP3820482A1 (de) | 2021-05-19 |
| IL280000A (en) | 2021-03-01 |
| CA3105717A1 (en) | 2020-01-30 |
| WO2020023191A1 (en) | 2020-01-30 |
| CN112584841A8 (zh) | 2021-06-18 |
| BR112021000279A8 (pt) | 2021-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3775203A4 (de) | Oligonukleotidzusammensetzungen und verfahren zur verwendung davon | |
| EP3790596A4 (de) | Oligonucleotidzusammensetzungen und verfahren zu ihrer verwendung | |
| EP3684364A4 (de) | Pyridazinone und verfahren zur verwendung davon | |
| EP3894392A4 (de) | Zusammensetzungen und verfahren zur behandlung von krebs | |
| EP3749344A4 (de) | Verfahren zur therapeutischen verwendung von exosomen und y-rnas | |
| EP3873387A4 (de) | Körper-engager und verwendungsverfahren | |
| EP3852533B8 (de) | Pyridazinone und verfahren zur verwendung davon | |
| EP3886853A4 (de) | Diarylhydantoiverbindungen und verfahren zur verwendung davon | |
| EP3752166A4 (de) | Trialkynverbindungsmittel und verfahren zur verwendung | |
| EP3740576A4 (de) | Therapeutische zusammensetzungen und verfahren zur herstellung und verwendung davon | |
| EP3638331A4 (de) | Dreidimensionale gewebezusammensetzungen und anwendungsverfahren | |
| EP3870203A4 (de) | Therapeutische kombinationen von tdfrps und zusätzlichen mitteln und verwendungsverfahren | |
| IL280000A (en) | Formulations for reducing tumors and methods of using them | |
| EP3829307A4 (de) | Wismuth-thiolzusammensetzungen und verwendungsverfahren | |
| EP3678701A4 (de) | Therapeutische proteinzusammensetzungen und verfahren zur herstellung und verwendung davon | |
| EP3784148A4 (de) | Implantate sowie verwendungs- und montageverfahren | |
| EP3758633A4 (de) | Implantate sowie verwendungs- und montageverfahren | |
| EP3675871A4 (de) | Zusammensetzungen und verfahren zur behandlung von fibrotischen krankheiten | |
| EP3941475A4 (de) | Pyridazinone und verfahren zur verwendung davon | |
| EP3960766A4 (de) | Tumortherapeutikum und verwendung davon | |
| EP3761989A4 (de) | Imidazodiazepinedione und verfahren zur verwendung davon | |
| EP4037715A4 (de) | Proteinmakromolekülkonjugate und verfahren zu ihrer verwendung | |
| EP3810118A4 (de) | Formulierungen von tegavivint und verwandten verbindungen | |
| EP3749691A4 (de) | Angptl8-bindende stoffe und verfahren zur verwendung davon | |
| AU2018292381A1 (en) | Cosmetic compositions and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20210203 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20220223 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 35/00 20060101ALI20220217BHEP Ipc: A61K 47/28 20060101ALI20220217BHEP Ipc: A61K 47/22 20060101ALI20220217BHEP Ipc: A61K 47/10 20170101ALI20220217BHEP Ipc: A61K 45/06 20060101ALI20220217BHEP Ipc: A61K 31/575 20060101ALI20220217BHEP Ipc: A61K 9/00 20060101ALI20220217BHEP Ipc: A61K 31/4015 20060101ALI20220217BHEP Ipc: A61K 31/08 20060101ALI20220217BHEP Ipc: A61K 38/17 20060101ALI20220217BHEP Ipc: A61K 38/00 20060101ALI20220217BHEP Ipc: A61K 31/7088 20060101AFI20220217BHEP |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
| 18W | Application withdrawn |
Effective date: 20230310 |